Healx
Edit

Healx

https://healx.io/
Last activity: 24.10.2024
Active
Categories: AnalyticsArtificial IntelligenceBioTechDataDevelopmentDrugHealthTechLearnPersonalTechnology
Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.
Followers
7.34K
Mentions
64
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $68.06M
Founded date: 2014

Investors 6

Funding Rounds 3

DateSeriesAmountInvestors
07.11.2019Series B$56.15M-
26.07.2018Series A$10M-
04.10.2016Series A$1.91MAmadeus Ca...

Mentions in press and media 64

DateTitleDescription
24.10.2024Innovate Cambridge launches strategy to accelerate innovation through increased startup investmentCambridge, UK has unveiled a plan to supercharge the impact of the Greater Cambridge area by doubling the rate at which it builds unicorns, doubling the venture capital investment the city’s startups receive, and creating twice as many scie...
06.09.2024August 2024's top 10 European tech deals you need to know aboutAugust was the slowest month YTD, with over €1.9 billion raised in some 203 deals. This figure represents a decrease of around 60 per cent compared to the previous month (in July European tech companies collected €5 billion). The August slo...
08.08.2024Healx Secures $47 Million to Tackle Rare Diseases with AI InnovationsIn a significant leap for the biotech sector, Healx, a clinical-stage company based in Cambridge, UK, has successfully raised $47 million in a Series C funding round. This infusion of capital is not just a financial boost; it’s a lifeline f...
07.08.2024Healx: Clinical-Stage Biotech Company Secures $47 Million In Series CHealx, an AI-enabled, clinical-stage biotech company specializing in rare diseases, announced it has raised $47 million in a Series C round. This Series C round was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s large...
09.02.2022Healx and Ovid Therapeutics enter strategic partnershipHealx and Ovid Therapeutics enter strategic partnership 09-02-2022 New York, NY and Cambridge, UK Ovid Therapeutics, a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases...
21.11.2021Europe’s AI laws will cost companies a small fortune – but the payoff is trustWe are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Artificial intelligence isn’t tomorrow’s technolo...
21.11.2021Europe’s AI laws will cost companies a small fortune – but the payoff is trustDid you miss a session from the Future of Work Summit? Head over to our Future of Work Summit on-demand library to stream. Artificial intelligence isn’t tomorrow’s technology — it’s already here. Now too is the legislation proposing to regu...
22.10.2021Healx receives IND and Orphan Drug Designation for fragile X clinical trialHealx receives IND and Orphan Drug Designation for fragile X clinical trial 22-10-2021 Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound...
22.10.2021Healx receives IND and Orphan Drug Designation for fragile X clinical trialHealx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one ...
20.10.2021UK startup Healx to begin clinical trial on repositioned drug for Fragile X syndromeThere are currently no approved cures for Fragile X syndrome — the most common cause of inherited intellectual disability. At the moment, the treatments are designed to manage symptoms, from anxiety to OCD or, in rare cases, seizures. But a...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In